123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study
A. M. Di Giacomo, G. Rossi, L. Calabro, A. Pascucci, V. Vegni, E. Simonetti, M. Colucci, M. Valente, G. Gibilisco, F. Frongia, M.F. Lofiego, G. Amato, H.N. Keer, A. Oganesian, D. Chan, D. Giannarelli, M. Ceccarelli, A. Anichini, A. Covre, M. Maio
{"title":"123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study","authors":"A. M. Di Giacomo, G. Rossi, L. Calabro, A. Pascucci, V. Vegni, E. Simonetti, M. Colucci, M. Valente, G. Gibilisco, F. Frongia, M.F. Lofiego, G. Amato, H.N. Keer, A. Oganesian, D. Chan, D. Giannarelli, M. Ceccarelli, A. Anichini, A. Covre, M. Maio","doi":"10.1016/j.iotech.2023.100595","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 69","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100595","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
